Agomab Therapeutics (AGMB) Operating Leases (2024 - 2025)
Agomab Therapeutics (AGMB) posted quarterly Operating Leases of $1.2 million for Q4 2025, down 13.93% year-over-year from $1.4 million in Q4 2024, and down 13.93% quarter-over-quarter from $1.4 million in Q4 2024.
Agomab Therapeutics (AGMB) Operating Leases (2024 - 2025) Analysis & Trends
Agomab Therapeutics' Operating Leases history runs 2 years deep, the most recent figure standing at $1.2 million for Q4 2025.
- In Q4 2025, Operating Leases fell 13.93% year-over-year to $1.2 million; the TTM figure through Dec 2025 stood at $1.2 million (down 13.93% YoY), while the FY2025 annual figure was $1.2 million, down 15.03% from the prior year.
- Operating Leases for Q4 2025 stood at $1.2 million, down from $1.4 million in the prior quarter.
- The five-year high for Operating Leases was $1.4 million in Q4 2024, with the low at $1.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - |
| 10 | Agomab Therapeutics | 7.27 Mn | -250.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.17 Mn |
| Dec 31, 2024 | 1.36 Mn |